Atlas Trials

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Clinical trial NCT05798663 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05798663
Sponsor
Alliance Foundation Trials, LLC.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2023-12-07
Primary completion
2026-11-01
Enrollment
178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.